{"id":"NCT01295112","sponsor":"Texas Retina Associates","briefTitle":"Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion","officialTitle":"Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-05","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2011-02-14","resultsPosted":"2017-10-18","lastUpdate":"2017-10-18"},"enrollment":68,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Ischemic Central Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"Active bevacizumab and Sham dexamethasone","otherNames":["Avastin® (bevacizumab)","Ozurdex® (dexamethasone intravitreal implant)"]},{"type":"DRUG","name":"Active bevacizumab and Active dexamethasone","otherNames":["Avastin® (bevacizumab)","Ozurdex® (dexamethasone intravitreal implant)"]}],"arms":[{"label":"Group 1","type":"SHAM_COMPARATOR"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.","primaryOutcome":{"measure":"The Primary Efficacy Endpoint is the Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks","timeFrame":"24 weeks","effectByArm":[{"arm":"Group 1","deltaMin":5,"sd":null},{"arm":"Group 2","deltaMin":19,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":[]}}